Galapagos signs manufacturing agreement for CAR-T cell therapy

Galapagos has signed a multi-year strategic manufacturing agreement with Landmark Bio, a collective endeavor to accelerate development and industrialization of next-generation genomic medicines. Landmark Bio will perform GMP manufacturing of clinical trial batches of Galapagos’ development programs of CAR T-cell therapies in hematology-oncology in the Boston metropolitan area. The manufacturing agreement aims at implementing Galapagos’ novel decentralized CAR-T manufacturing model, designed to enable clinicians to administer CAR T-cells within a median of seven days of leukapheresis, thereby aiming to address important limitations of current CAR-T treatments. Financial terms of the agreement were not disclosed.